Ensuring Sample Quality for Biomarker Discovery Studies – Use of ICT Tools to Trace Biosample Life-cycle

Cancer Genomics - Proteomics

MARIO ROSELLI²  RAFFAELE PALMIROTTA⁶  SILVIA RIONDINO¹  ANTONELLA SPILA³  JHESSICA ALESSANDRONI³  ROBERTA D'ALESSANDRO³  UMBERTO NANNI⁴  VINCENZO FORMICA²  DAVID DELLA-MORTE¹  FIORELLA GUADAGNI⁵  PATRIZIA FERRONI⁶ 

[1] ioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, Italyedical Oncology, Policlinico Tor Vergata Biospecimen Cancer Biorepository (IIV Bio. Ca. Re), Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Rome, ItalyioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, ItalyioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, Italyedical Oncology, Policlinico Tor Vergata Biospecimen Cancer Biorepository (IIV Bio. Ca. Re), Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Rome, Italyedical Oncology, Policlinico Tor Vergata Biospecimen Cancer Biorepository (IIV Bio. Ca. Re), Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Rome, ItalyioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, Italyedical Oncology, Policlinico Tor Vergata Biospecimen Cancer Biorepository (IIV Bio. Ca. Re), Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Rome, Italy;edical Oncology, Policlinico Tor Vergata Biospecimen Cancer Biorepository (IIV Bio. Ca. Re), Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Rome, Italyedical Oncology, Policlinico Tor Vergata Biospecimen Cancer Biorepository (IIV Bio. Ca. Re), Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Rome, Italyedical Oncology, Policlinico Tor Vergata Biospecimen Cancer Biorepository (IIV Bio. Ca. Re), Department of Internal Medicine, University of Rome “Tor Vergata”, Tor Vergata Clinical Center, Rome, Italy;ioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, ItalyioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, ItalyioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, Italy;epartment of Computer, Control and Management Engineering “Antonio Ruberti”, “Sapienza” University, Rome, Italyepartment of Computer, Control and Management Engineering “Antonio Ruberti”, “Sapienza” University, Rome, Italyepartment of Computer, Control and Management Engineering “Antonio Ruberti”, “Sapienza” University, Rome, Italy;ioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, Italyan Raffaele Rome University, IRCCS San Raffaele Pisana, Research Center, Rome, ItalyioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, ItalyioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, Italyan Raffaele Rome University, IRCCS San Raffaele Pisana, Research Center, Rome, Italyan Raffaele Rome University, IRCCS San Raffaele Pisana, Research Center, Rome, ItalyioBIM - Multidisciplinary Interinstitutional BioBank, IRCCS San Raffaele Pisana – Research Center, Rome, Italyan Raffaele Rome University, IRCCS San Raffaele Pisana, Research Center, Rome, Italy;an Raffaele Rome University, IRCCS San Raffaele Pisana, Research Center, Rome, Italyan Raffaele Rome University, IRCCS San Raffaele Pisana, Research Center, Rome, Italyan Raffaele Rome University, IRCCS San Raffaele Pisana, Research Center, Rome, Italy

关键词: Biomarker discovery;    biobanking;    ICT tools;    sample quality;    review;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

The growing demand of personalized medicine marked the transition from an empirical medicine to a molecular one, aimed at predicting safer and more effective medical treatment for every patient, while minimizing adverse effects. This passage has emphasized the importance of biomarker discovery studies, and has led sample availability to assume a crucial role in biomedical research. Accordingly, a great interest in Biological Bank science has grown concomitantly. In biobanks, biological material and its accompanying data are collected, handled and stored in accordance with standard operating procedures (SOPs) and existing legislation. Sample quality is ensured by adherence to SOPs and sample whole life-cycle can be recorded by innovative tracking systems employing information technology (IT) tools for monitoring storage conditions and characterization of vast amount of data. All the above will ensure proper sample exchangeability among research facilities and will represent the starting point of all future personalized medicine-based clinical trials.

【 授权许可】

Unknown